Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | SCD | O00767 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311932 | 0.90 | HPGDS (0.41) | SLC6A7RIPK1HTR2BHPGDS | |
| SCHEMBL2318597 | 0.84 | RIPK1 (0.38) | SLC6A7RIPK1HPGDSSCDROCK2 | |
| SCHEMBL2833196 | 0.82 | RPS6KB1 (0.38) | SLC6A7RIPK1PIM1HPGDSSCD | |
| SCHEMBL2843739 | 0.78 | MTOR (0.36) | HTR2BPIM1HPGDSKITCHRNB2 | |
| SCHEMBL2836908 | 0.77 | KDM2B (0.47) | HTR2BHPGDSCHRNB2CHRNA3 | |
| SCHEMBL2837386 | 0.77 | HPGDS (0.54) | HTR2BHPGDS | |
| SCHEMBL2317090 | 0.75 | HPGDS (0.54) | HTR2BHPGDSCHRNB2CHRNA3 | |
| SCHEMBL2843317 | 0.74 | HTR2B (0.43) | HTR2BHPGDS | |
| SCHEMBL2834201 | 0.74 | HPGDS (0.46) | HTR2BHPGDS | |
| SCHEMBL2838119 | 0.73 | NAMPT (0.42) | HTR2BHPGDSROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350059-B1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEM CO (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9126973-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-04-09 | — | — | US | disclosed |
| US-8536185-B2 | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-09-17 | — | — | US | disclosed |
| US-8450326-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2013-03-28 | — | — | US | disclosed |
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | CAYMAN CHEMICAL COMPANY (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075990-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | SLC6A7 4119/4885RIPK1 2443/4885GRM5 1124/4885 |
| US-20130079375-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | SLC6A7 4119/4885RIPK1 2443/4885GRM5 1124/4885 |
| US-20150099748-A1 | MULTIHETEROARYL COMPOUNDS AS INHIBITORS OF H-PGDS AND THEIR USE FOR TREATING PROSTAGLANDIN D2 MEDIATED DISEASES | HPGDS, PTGIS, PTGES | SLC6A7 4119/4885RIPK1 2443/4885GRM5 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.